Navigation Links
HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
Date:5/8/2012

FRAMINGHAM, Mass. and SYDNEY, May 8, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that enrollment is complete in ENDURANCE, the Company's pivotal Destination Therapy clinical study to evaluate the use of the HeartWare® Ventricular Assist System in patients with end-stage heart failure.

"Completing enrollment in this, the largest head-to-head ventricular assist device clinical trial to date, is a major achievement and we look forward to following this Destination Therapy patient population to primary endpoint over the next two years," said Doug Godshall, President and Chief Executive Officer.  "We are thankful for the diligence of the investigators and site coordinators at the 50 U.S. hospitals in the ENDURANCE study.  With enrollment of the study complete, we are pleased to report that more than 2,000 end stage heart failure patients globally have received the HeartWare Ventricular Assist System."

ENDURANCE is a randomized, controlled, unblinded, multi-center clinical trial to evaluate the use of the HeartWare Ventricular Assist System as a Destination Therapy in advanced heart failure patients.  The non-inferiority study enrolled 450 patients with end-stage heart failure who have not responded to standard medical management and who are ineligible for cardiac transplantation.  Patients were randomly selected to receive either the HeartWare Ventricular Assist System or, as part of a control group, any alternative LVAD approved by the FDA for Destination Therapy, in a 2:1 ratio.  Each patient receiving the HeartWare Ventricular Assist System or control LVAD will be followed to the primary endpoint at two years, with a subsequent follow-up p
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
2. Heartware Schedules First Quarter Conference Call And Webcast
3. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
4. HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
5. HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast
6. HeartWare Schedules Fourth Quarter Conference Call and Webcast
7. HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist System
8. HeartWare to Present at the Oppenheimer 22nd Annual Healthcare Conference
9. HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Conference
10. HeartWare to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
11. HeartWare to Present at the Credit Suisse 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... Nektar Therapeutics (Nasdaq: NKTR ) today reported its ... Cash and investments in marketable securities at ... million at March 31, 2014."The second half of 2014 will ... to significant milestones for a number of our late-stage clinical ... of Nektar. "The first of these is the potential US ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
(Date:8/1/2014)... DC (PRWEB) August 01, 2014 ... offer health plans and employers effective options to ... narrow networks argue that they can enhance formulary ... administrative fees. Consultants report that nearly all PBMs ... to requests for proposals. The Aug. 12 ...
(Date:8/1/2014)... 2014 Millions of women suffer with ... and in some cases the arms, causing an abnormal ... 17 million women in the U.S. alone are affected. ... the pain, embarrassment and discomfort caused by lipedema, it’s ... are unaware that this is a disease,” says Dr. David ...
(Date:8/1/2014)... August 01, 2014 Get the report ... with PitchBook presents the 3Q 2014 Private Equity Breakdown ... equity investment, exits and fundraising activity in the second ... help plan for private equity endeavors for the remainder ... to download it now. , About Merrill DataSite , ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The ... important developments about chemical listings, appellate decisions, litigation ... that may affect compliance with California's Proposition 65. ... to the law, regulations, history and trends impacting ... the fourth installment of the series which adds ...
(Date:7/31/2014)... recently used birth control pills containing high-dose estrogen and ... breast cancer, whereas women using some other formulations did ... , a journal of the American Association for Cancer ... oral contraceptives [birth control pills] in the past year ... to never or former oral contraceptive use, and that ...
Breaking Medicine News(10 mins):Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Recent use of some birth control pills may increase breast cancer risk 2
... is a sad day for the American labor movement and ... the bottom up, rather than the top down.SEIU,s press release ... It also is predictable that Hearing Officer Ray Marshall, former ... Stern to conduct the hearing would do the job he ...
... 22 Novo Nordisk, a global healthcare company focusing on ... "100 Best Companies to Work For" awards issue. This is ... award -- one of the most influential business scorecards in ... For" are historically good performers in the marketplace for not ...
... 22 Missouri Congressman Roy Blunt today reflected on the ... v. Wade by speaking with the Missouri-Illinois Right to Life ... in sending a letter to President Barack Obama urging him ... "The last few years are the first time since I,ve ...
... preventable blindnessOAK BROOK, Ill., Jan. 22 The ... http://www.newscom.com/cgi-bin/prnh/20081014/DC38855LOGO ) Who: Former President ... Lions Clubs International President Albert Brandel; ... Dedication of the "Gift of Sight" statue, ...
... 22 Griffin Hospital has been honored with a 10th year ... Griffin ranked 62 on the 2009 list released today. Griffin is ... ten years.Griffin was first invited to apply for selection to the ... since. FORTUNE has issued the list of "100 Best Companies to ...
... announced today that,the physicians of Midwest Pulmonary and ... , The physicians are Susan ... Plumb, M.D. All are board-certified in pulmonology,and critical care ... the treatment of sleep disorders. , ...
Cached Medicine News:Health News:Statement by UHW on SEIU's Claims Regarding SEIU-Trusteeship Hearing Process Chaired by Ray Marshall 2Health News:Novo Nordisk Makes its Debut in FORTUNE's '100 Best Companies to Work For' 2Health News:Novo Nordisk Makes its Debut in FORTUNE's '100 Best Companies to Work For' 3Health News:Blunt Marks Anniversary of Roe v. Wade, Signs Letter in Defense of Pro-Life Legislation 2Health News:Blunt Marks Anniversary of Roe v. Wade, Signs Letter in Defense of Pro-Life Legislation 3Health News:Former President Jimmy Carter Dedicates 'Gift of Sight' Statue at Lions Club International Headquarters in Recognition of Lions' Blindness Prevention Efforts 2Health News:Griffin Honored with Tenth Year on FORTUNE Best Companies to Work for List 2Health News:Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group 2
A sturdy, robust stool. Gas operated height adjustment for convenience....
Lacrimal Cannulas, 19 g. shaft tapering to 23 g. cannula, straight. Overall length 37.5 mm. 5/box....
Viscoelastic Cannula, 27 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 27 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box....
Medicine Products: